- Amyris is a bio-manufacturer, producing alternative ingredients to be used in the production of beauty and wellness products, in addition to producing consumer goods.
- The company exhibits 47% growth in product revenues, has reduced debts, and its cash position has improved.
- It faces some margin compression risks in case commodity price rise.
- The company has a multi-pronged strategy to continue its astounding growth.
- Valuations are high, but given the 30% dip from March highs, this NASDAQ constituent is an opportunistic buy, especially given that it is involved in the development of a COVID vaccine.
For further details see:
Finding Value In Beauty And Wellness Through Amyris